We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Signaling Pathway Links Bone Development to the Parasympathetic Nervous System

By LabMedica International staff writers
Posted on 19 Sep 2012
A molecular signaling pathway based on the cytokine interleukin-1 (IL-1) has been found to play a critical regulatory role in the formation and growth of bone mass in the developing individual.

A team of investigators at the Hebrew University of Jerusalem (Israel) were studying the relationship between bone development and the parasympathetic nervous system (PSNS). More...
To trace linkages within this system they injected pseudorabies virus into the thighbones of a population of laboratory mice and then followed the trail of the virus as it migrated towards the brain.

Results published in the September 4, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA (PNAS) showed that following injection into bone the virus could be detected in the brain in regions known to be specific for the parasympathetic subsystem. Furthermore, results indicated that effects of the parasympathetic system on bone development were similar to those previously attributed to IL-1 activity.

Genetically engineered mice with silenced IL-1 receptor signaling in the central nervous system due to brain-specific overexpression of a human IL-1 receptor antagonist displayed increased bone resorption and low bone mass.

This newly identified neuronal pathway, which connects interleukin-1 in the brain and the parasympathetic subsystem, was found to regulate heart rate in addition to its effects on bone growth and development. Disruption of interleukin-1 in the brain and the parasympathetic system has been observed in disorders such as depression, Alzheimer's disease, and epilepsy, which are often accompanied by low bone density and osteoporosis.

"The connection between the brain and the bone in general and the involvement of the newly discovered pathway in particular is a new area of research about which we still know very little,” said senior author Dr. Itai Bab, professor of oral pathology at the Hebrew University of Jerusalem. "The new findings, discovered in our Hebrew University laboratories, highlight for the first time an important physiological role for the connection between interleukin-1 in the brain and the autonomic nervous system."

Related Links:
Hebrew University of Jerusalem



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.